JP2023135646A5 - - Google Patents
Info
- Publication number
- JP2023135646A5 JP2023135646A5 JP2023039398A JP2023039398A JP2023135646A5 JP 2023135646 A5 JP2023135646 A5 JP 2023135646A5 JP 2023039398 A JP2023039398 A JP 2023039398A JP 2023039398 A JP2023039398 A JP 2023039398A JP 2023135646 A5 JP2023135646 A5 JP 2023135646A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- fusion protein
- vegf receptor
- receptor fusion
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (20)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263319869P | 2022-03-15 | 2022-03-15 | |
| US63/319,869 | 2022-03-15 | ||
| US202263404512P | 2022-09-07 | 2022-09-07 | |
| US63/404,512 | 2022-09-07 | ||
| US202263404893P | 2022-09-08 | 2022-09-08 | |
| US63/404,893 | 2022-09-08 | ||
| US202263411594P | 2022-09-29 | 2022-09-29 | |
| US63/411,594 | 2022-09-29 | ||
| US202263412165P | 2022-09-30 | 2022-09-30 | |
| US63/412,165 | 2022-09-30 | ||
| US202263421298P | 2022-11-01 | 2022-11-01 | |
| US63/421,298 | 2022-11-01 | ||
| US202263434920P | 2022-12-22 | 2022-12-22 | |
| US63/434,920 | 2022-12-22 | ||
| US202363444480P | 2023-02-09 | 2023-02-09 | |
| US63/444,480 | 2023-02-09 | ||
| US202363447582P | 2023-02-22 | 2023-02-22 | |
| US63/447,582 | 2023-02-22 | ||
| CA3190733A CA3190733A1 (en) | 2022-03-15 | 2023-02-22 | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders |
| CA3,190,733 | 2023-02-22 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023135646A JP2023135646A (ja) | 2023-09-28 |
| JP2023135646A5 true JP2023135646A5 (enExample) | 2026-03-24 |
Family
ID=85704021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023039398A Pending JP2023135646A (ja) | 2022-03-15 | 2023-03-14 | 血管新生性眼障害の処置のための長期高用量ｖｅｇｆアンタゴニストレジメン |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240024420A1 (enExample) |
| EP (1) | EP4245312A1 (enExample) |
| JP (1) | JP2023135646A (enExample) |
| KR (1) | KR20230135013A (enExample) |
| CN (1) | CN119136823A (enExample) |
| AU (2) | AU2023233561A1 (enExample) |
| CA (1) | CA3253640A1 (enExample) |
| CL (2) | CL2024002733A1 (enExample) |
| IL (1) | IL315374A (enExample) |
| JO (1) | JOP20240202A1 (enExample) |
| MX (1) | MX2024011079A (enExample) |
| TW (1) | TW202400214A (enExample) |
| WO (1) | WO2023177691A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20240329A1 (es) | 2019-06-05 | 2024-02-27 | Regeneron Pharma | Dispositivos y metodos para administracion de dosis de precision |
| FI4185318T3 (fi) | 2021-05-17 | 2025-10-13 | Regeneron Pharma | Pitkäaikaisia, suuren annoksen VEGF-antagonistihoitoja angiogeenisten silmäsairauksien hoitoon |
| US12649031B2 (en) | 2021-09-08 | 2026-06-09 | Regeneron Pharmaceuticals, Inc. | Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| CN121712520A (zh) | 2023-06-23 | 2026-03-20 | 瑞泽恩制药公司 | 用于治疗血管生成性眼病的延长的高剂量vegf拮抗剂方案 |
| WO2025217334A1 (en) * | 2024-04-09 | 2025-10-16 | Regeneron Pharmaceuticals, Inc. | Low concentration vegf receptor fusion protein containing formulations |
| KR20260096819A (ko) * | 2024-12-13 | 2026-06-24 | 리제너론 파아마슈티컬스, 인크. | 망막 정맥 폐쇄에 속발하는 혈관신생 눈 장애의 치료를 위한 연장된 고용량 vegf 길항제 레지먼 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7396664B2 (en) | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
| AR046510A1 (es) | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
| ES2381014T3 (es) | 2004-06-08 | 2012-05-22 | Chengdu Kanghong Biotechnologies Co., Ltd. | Proteína quimérica inhibidora de la angiogénesis y el uso |
| CN100502945C (zh) | 2006-03-31 | 2009-06-24 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在治疗眼睛疾病中的应用 |
| IL318292A (en) | 2017-12-13 | 2025-03-01 | Regeneron Pharma | Devices and methods for administering precise doses |
| RS67656B1 (sr) | 2018-05-10 | 2026-02-27 | Regeneron Pharma | Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora |
| PE20240329A1 (es) | 2019-06-05 | 2024-02-27 | Regeneron Pharma | Dispositivos y metodos para administracion de dosis de precision |
| AU2020326243A1 (en) * | 2019-08-06 | 2022-02-17 | F. Hoffmann-La Roche Ag | Personalized treatment of ophthalmologic diseases |
| FI4185318T3 (fi) * | 2021-05-17 | 2025-10-13 | Regeneron Pharma | Pitkäaikaisia, suuren annoksen VEGF-antagonistihoitoja angiogeenisten silmäsairauksien hoitoon |
-
2023
- 2023-03-14 TW TW112109388A patent/TW202400214A/zh unknown
- 2023-03-14 IL IL315374A patent/IL315374A/en unknown
- 2023-03-14 CN CN202380025712.6A patent/CN119136823A/zh active Pending
- 2023-03-14 CA CA3253640A patent/CA3253640A1/en active Pending
- 2023-03-14 WO PCT/US2023/015225 patent/WO2023177691A1/en not_active Ceased
- 2023-03-14 AU AU2023233561A patent/AU2023233561A1/en active Pending
- 2023-03-14 JP JP2023039398A patent/JP2023135646A/ja active Pending
- 2023-03-14 US US18/121,499 patent/US20240024420A1/en active Pending
- 2023-03-15 AU AU2023201638A patent/AU2023201638A1/en active Pending
- 2023-03-15 KR KR1020230034231A patent/KR20230135013A/ko active Pending
- 2023-03-15 EP EP23162090.7A patent/EP4245312A1/en active Pending
-
2024
- 2024-09-09 JO JOJO/P/2024/0202A patent/JOP20240202A1/ar unknown
- 2024-09-10 MX MX2024011079A patent/MX2024011079A/es unknown
- 2024-09-11 CL CL2024002733A patent/CL2024002733A1/es unknown
-
2025
- 2025-06-18 CL CL2025001818A patent/CL2025001818A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023135645A5 (enExample) | ||
| US11071780B2 (en) | Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab | |
| AU2022275786B2 (en) | Extended, high dose VEGF antagonist regimens for treatment of angiogenic eye disorders | |
| EP4245313A1 (en) | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders | |
| EP4245312A1 (en) | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders | |
| AU2021221401B2 (en) | Stable peptide compositions | |
| JP2021505535A (ja) | 血管形成眼障害を処置するためのｖｅｇｆアンタゴニストの使用 | |
| EP4480491A1 (en) | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders | |
| HK40099476A (en) | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders | |
| CA3190733A1 (en) | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders | |
| EA051980B1 (ru) | Расширенные схемы применения высоких доз антагониста vegf для лечения ангиогенных нарушений со стороны глаза | |
| HK40099475A (en) | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders | |
| CA3190726A1 (en) | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders | |
| HK40094129B (en) | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders | |
| HK40094129A (en) | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders | |
| HK40119109A (en) | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders | |
| Albrecht et al. | REGENERON REGENERON PHARMACEUTICALS, INC. 777 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591-6707 |